Department of Pediatrics, Northwestern University Feinberg School of Medicine, 225 East Chicago Avenue, Box 20, Chicago, IL 60611, USA.
Nat Rev Rheumatol. 2015 Aug;11(8):475-82. doi: 10.1038/nrrheum.2015.54. Epub 2015 Apr 28.
This Review summarizes recent advances in understanding of the pathologic processes and pathophysiologic mechanisms leading to coronary arteritis in Kawasaki disease, and describes current approaches to its treatment. Kawasaki disease is the most common cause of acquired heart disease among children in developed countries, in whom the resulting coronary artery abnormalities can cause myocardial ischaemia, infarction and even death. Epidemiologic data strongly suggest an infectious aetiology, although the causative agent has yet to be identified. Genetic factors also increase susceptibility to Kawasaki disease, as indicated by its strikingly high incidence rate in children of Asian ethnicity and by an increased incidence in first-degree family members. The treatment of Kawasaki disease is based on timely administration of intravenous immunoglobulin and aspirin. However, the management of patients who do not respond to this standard therapy remains challenging; although several options are available, comparative data on which to base treatment decisions are scarce. The added value of adjunctive therapy with corticosteroids in patients at particularly high risk of coronary complications has been demonstrated in Japanese populations, but identification of high-risk patients has proven to be difficult in ethnically diverse populations.
这篇综述总结了对川崎病导致冠状动脉炎的病理过程和病理生理机制的最新认识,并描述了目前对该病的治疗方法。川崎病是发达国家儿童获得性心脏病的最常见病因,其导致的冠状动脉异常可引起心肌缺血、梗死,甚至死亡。流行病学数据强烈提示该病具有感染性病因,但致病因子尚未确定。遗传因素也会增加川崎病的易感性,这从该病在亚洲裔儿童中的极高发病率以及一级亲属发病率增加中可见一斑。川崎病的治疗基于及时给予静脉注射免疫球蛋白和阿司匹林。然而,对于那些对这种标准治疗无反应的患者,其管理仍然具有挑战性;尽管有几种选择,但缺乏可用于治疗决策的比较数据。在日本人群中,皮质类固醇辅助治疗对冠状动脉并发症风险极高的患者具有附加价值,但在种族多样化的人群中,确定高危患者一直具有难度。